Read by QxMD icon Read

Irvine-Gass Syndrome

Chun-Ju Lin, Yi-Yu Tsai
BACKGROUND/PURPOSE: To present the patient treated for pseudophakic cystoid macular edema with intravitreal aflibercept. METHODS: Interventional case report. CASE: An 83-year-old woman presented with decreased vision 1 month after uneventful cataract surgery. After failure to respond to posterior subtenons triamcinolone and three Ranibizumab injections, the patient responded to one intravitreal aflibercept injection. Recurrence occurred two months later, and therefore three monthly injections were then given...
September 8, 2016: Retinal Cases & Brief Reports
Ilias Georgalas, Petros Petrou, Dionysios Pagoulatos, Dimitrios Papaconstantinou, Ioannis Tservakis
No abstract text is available yet for this article.
August 17, 2016: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
Stephanie M Llop, Eduardo Gonzalez, Andres Emanuelli
PURPOSE: To report a case of spontaneous closure of a full-thickness macular hole after a posterior subtenon injection of triamcinolone in a patient with Irvine-Gass syndrome. METHODS: Case report and literature review. RESULTS: A 70-year-old man presented to the retina clinic with visual disturbance in his right eye after an uneventful cataract surgery. Patient was found to have macular edema associated with a full-thickness macular hole, treated with a posterior subtenon injection of triamcinolone with subsequent spontaneous closure of the hole and excellent visual acuity...
May 27, 2016: Retinal Cases & Brief Reports
Chafik Keilani, Aziz Halalchi, Désiré Wakpi Djeugue, Anne Regis, Samir Abada
PURPOSE: Irvine-Gass syndrome is a macular edema (ME) that specifically occurs after cataract surgery. Its incidence varies from 0.2-2%. The purpose of this study is to evaluate the effectiveness of intravitreal dexamethasone implant injections in patients with Irvine-Gass syndrome. METHODS: Patients with ME secondary to cataract surgery who underwent intravitreal injections of dexamethasone implant between December 2011 to October 2014 at François-Quesnay hospital (Mantes-la-Jolie, France) were retrospectively reviewed...
April 11, 2016: Thérapie
David Bellocq, Vincent Pierre-Kahn, Frédéric Matonti, Carole Burillon, Nicolas Voirin, Corinne Dot, Jad Akesbi, Solange Milazzo, Stéphanie Baillif, Vincent Soler, Benjamin Wolff, Claire Scemama, Ariane Malclès, Michel Weber, Laurent Kodjikian
AIM: To assess the effectiveness of intravitreal dexamethasone implants for treating postsurgical macular oedema (PSMO) including Irvine-Gass syndrome and determining the predictive factors of treatment response. METHODS: Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. One hundred patients were included between April 2011 and June 2014, with a minimum of 1-year follow-up. Patients received dexamethasone implant 0...
May 17, 2016: British Journal of Ophthalmology
L Bernal, B Estévez
OBJECTIVE: To describe a case of corneal toxicity after migration of a dexamethasone implant into the anterior chamber. CASE REPORT: A 62-year-old man with aphakia and a history of vitrectomy received a dexamethasone implant for a refractory Irvine-Gass syndrome. Thirty days later, the implant migrated into the anterior chamber causing endothelial contact with secondary corneal oedema that justified the removal of the implant without resolution of the oedema. DISCUSSION: Clinical tolerability to dislocated implant is poor in cases with pre-existing corneal oedema, and because of this, it must be removed early...
June 2016: Archivos de la Sociedad Española de Oftalmología
Alexandr Stepanov, Marco Codenotti, Andrea Ramoni, Matteo Prati, Nada Jiraskova, Pavel Rozsival, Francesco Bandello
PURPOSE: Intravitreal implantation of dexamethasone implant (Ozurdex®) is being widely used for the treatment of macular edema (ME) after branch or central retinal vein occlusion, diabetic ME, and persistent ME associated with uveitis or Irvine-Gass syndrome. We describe a complication: migration of the dexamethasone implant into the anterior chamber through basal iridectomy (Ando) in a pseudophakic patient with development of corneal edema and secondary high intraocular pressure. METHODS: This is a case report of migration of Ozurdex® through basal iridectomy in a pseudophakic patient with iris claw lens...
May 2016: European Journal of Ophthalmology
Wolfgang J Mayer, Stefanie Kurz, Armin Wolf, Daniel Kook, Thomas Kreutzer, Anselm Kampik, Siegfried Priglinger, Christos Haritoglou
PURPOSE: To investigate the effectiveness and safety of a dexamethasone implant (Ozurdex) to treat pseudophakic macular edema (Irvine-Gass syndrome). SETTING: Department of Ophthalmology, Ludwig-Maximilians-University Munich, Munich, Germany. DESIGN: Prospective nonrandomized study. METHODS: Preoperatively and in 12 monthly postoperative intervals, a complete ophthalmic examination was performed in study patients, including measurement of corrected distance visual acuity (CDVA) using the standard Early Treatment Diabetic Retinopathy Study chart, intraocular pressure, foveal thickness using spectral-domain optical coherence tomography (SD-OCT), and retinal sensitivity (mean defect depth) using microperimetry...
September 2015: Journal of Cataract and Refractive Surgery
C Landré, A Zourdani, P Gastaud, S Baillif
PURPOSE: To evaluate the efficacy of dexamethasone 0.7 mg intravitreal implant in patients with postoperative cystoid macular edema. MATERIALS AND METHODS: Fourteen patients' charts with postoperative cystoid macular edema were retrospectively reviewed. The main outcome measures were best-corrected visual acuity (BCVA) and mean central retinal thickness (CRT). RESULTS: Patients' mean age was 72.1 years old. Five patients were diabetic. All patients had previously been treated with non-steroidal anti-inflammatory drops...
January 2016: Journal Français D'ophtalmologie
Melissa K Shields, Paul A Adler, Dujon R W Fuzzard, Rajeeve Chalasani, Joanne M Y Teong
PURPOSE: To report a case of acute bilateral Irvine-Gass syndrome. METHODS: This is an observational case report. RESULTS: An 82-year-old man with no significant ocular history developed postsurgical pseudophakic cystoid macular edema (CME; Irvine-Gass syndrome) on consecutive phacoemulsification cataract surgeries. His initial first-eye (left) CME developed 25 days after surgery and was managed with topical preparations of dexamethasone 0...
January 2015: Case Reports in Ophthalmology
L Ortega-Evangelio, T Diago Sempere
OBJECTIVE: To evaluate the efficacy of intravitreal dexamethasone implant on the treatment of pseudophakic macular edema (PME). MATERIAL AND METHODS: A retrospective, observational, descriptive study was conducted on 4 patients who received an intravitreal injection of dexamethasone implant due to PME in the period from 1st January 2013 to 31st December 2013 in the Hospital Universitario de La Ribera (Alzira, Valencia, Spain). A complete ophthalmic examination was performed on these patients...
July 2015: Archivos de la Sociedad Española de Oftalmología
A Degoumois, J Akesbi, C Laurens, F-T Rodallec, R Adam, E Blumen-Ohana, O Laplace, C Virevialle, B Le Dû, V Guyader, J-P Nordmann
INTRODUCTION: The intravitreal dexamethasone implant has shown efficacy in the treatment of macular edema (ME) arising after retinal venous occlusions (central or branch), and in the treatment of non-infectious uveitis. The purpose of this study was to evaluate the efficacy of this implant in the treatment of other diffuse macular edemas with an inflammatory mechanism. MATERIALS AND METHODS: We carried out a retrospective cohort study over 2 years: from January 2012 to December 2013, including all patients who received at least one injection of intravitreal dexamethasone implant, excluding venous occlusions and non-infectious uveitis...
February 2015: Journal Français D'ophtalmologie
David Bellocq, Jean-François Korobelnik, Carole Burillon, Nicolas Voirin, Corinne Dot, Eric Souied, John Conrath, Solange Milazzo, Pascale Massin, Stéphanie Baillif, Laurent Kodjikian
AIM: To assess the effectiveness and safety of intravitreal dexamethasone implants for treating post-surgical macular oedema, including Irvine-Gass syndrome refractory to first-line treatments. METHODS: Descriptive, observational, retrospective, consecutive, uncontrolled, multicentre, national case series. 50 patients were included in the study between March 2011 and June 2013 with a minimum 6 months follow-up. At baseline, each patient received a dexamethasone implant 0...
July 2015: British Journal of Ophthalmology
Vito Fenicia, Marco Balestrieri, Andrea Perdicchi, Maurizio MauriziEnrici, Martina DelleFave, Santi Maria Recupero
PURPOSE: To evaluate the efficacy of 2 dexamethasone intravitreal implants and 1 ranibizumab intravitreal injection after a bilateral postoperative complication of cataract surgery as pseudophakic cystoid macular edema. PATIENTS AND METHODS: A 70-year-old male patient with systemic hypertension developed a progressive cystoid macular edema (CME) in both eyes starting between 10 and 20 days after cataract surgery. Two intravitreal dexamethasone implants and 1 ranibizumab injection were administered; first in the right eye (RE) and then in the left eye (LE)...
May 2014: Case Reports in Ophthalmology
Panagiotis G Mitropoulos, Irini P Chatziralli, Vasileios G Peponis, Evangelos Drakos, Efstratios A Parikakis
PURPOSE: The purpose of our study was to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic cystoid macular edema (CME). METHODS: This retrospective study comprised 7 eyes with CME treated with intravitreal ranibizumab. Patients were examined at 1 week and 1 month after injection and monthly thereafter. Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT)...
June 2015: Ocular Immunology and Inflammation
Daniel F Kiernan, Seenu M Hariprasad
No abstract text is available yet for this article.
November 1, 2013: Ophthalmic Surgery, Lasers & Imaging Retina
Marilita M Moschos, Zisis Gatzioufas, Tryfon Rotsos, Chrysanthos Symeonidis, Xuefei Song, Berthold Seitz
BACKGROUND: Macular edema (ME) is caused by abnormal retinal capillary permeability and has also been described as a postoperative complication of cataract surgery (Irvine-Gass syndrome). OBJECTIVE: To present a patient with Irvine-Gass syndrome in the right eye complicated with a macular hole (MH) in the same eye and possible associations between these two entities. CASE REPORT: A 72-year-old male with a history of uneventful bilateral cataract surgery was followed-up with biomicroscopy and optical coherence tomography (OCT)...
2013: Clinical Ophthalmology
Bartosz Izdebski, Zofia Michalewska, Krzysztof Dziegielewski, Jerzy Nawrocki, Dominik Odrobina
PURPOSE: To determine clinical effect of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema after cataract surgery. MATERIAL AND METHODS: Four eyes of four patients treated with 1 intravitreal injection of 1.25 mg Avastin. In three cases duration of cystoid macular edema was less then 4 months, in one eye cystoid macular edema was chronic (more than 4 months). Visual acuity and clinical effect in spectral optical coherence tomography (central retinal thickness and fovea anatomy) was examined before and after intravitreal injection...
2013: Klinika Oczna
M Brunner, I Haueter, C Valmaggia
BACKGROUND: The efficacy of a single dose of Ozurdex® was evaluated over a 6-month period in eyes with macular edema due to retinal vein occlusion and intraocular inflammatory disease. HISTORY AND SIGNS: 20 eyes of 20 consecutive patients with macular edema received a single injection of Ozurdex® (intravitreal dexamethasone implant 0.7 mg). Patients with branch retinal vein occlusion (n = 11), central retinal vein occlusion (n = 6), non-infectious posterior uveitis (n = 1) and Irvine-Gass Syndrome (n = 2) were included...
April 2013: Klinische Monatsblätter Für Augenheilkunde
Marco Dutra Medeiros, Rafael Navarro, José Garcia-Arumí, Carlos Mateo, Borja Corcóstegui
PURPOSE: To evaluate the effectiveness of a single intravitreal injection of dexamethasone implant, over 6 months in patients with recalcitrant CME due to Irvine-Gass syndrome. METHODS: Retrospective review of the medical records of nine patients with refractory macular edema (ME) due to Irvine-Gass syndrome, who underwent a single intravitreal injection of dexamethasone implant, Ozurdex, between November 2010 and January 2012, at the Instituto de Microcirurgia Ocular, Barcelona, Spain...
May 2013: Investigative Ophthalmology & Visual Science
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"